(Monmouth Junction NJ USA)– TAXIS Pharmaceuticals announced that a profile of the company appears in the June 2020 issue of Nature BioPharma Dealmakers with a focus on infectious diseases. The TAXIS profile will also appear in the infectious disease insert appearing in the June 2020 issues of Nature Biotechnology and Nature Reviews Drug Discovery. “We’re exceptionally pleased to begin telling a broader audience about TAXIS Pharmaceuticals’ advances in our anti-resistance drug platform” said Gregory Mario, CEO of TAXIS Pharmaceuticals. Interested parties can download the profile by clicking here.
ABOUT TAXIS PHARMACEUTICALS
TAXIS Pharmaceuticals, Inc. is a clinical stage company developing anti-resistance drug candidates that enable the re-use of the most widely prescribed generic antibiotics against antibiotic-resistant ESKAPE pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter species). Our TAXISTANCE® anti-resistance drug platform is focused on the disruption of the foundation of bacterial cell wall architecture to address elemental forms of drug resistance. Our most advanced drug candidate, oral TXA709, will be enrolling an additional Phase I human safety clinical trial in healthy volunteers for development as an anti-resistance drug to be used in combination with obsolete antibiotics as a fully oral anti-MRSA treatment. TXA709 targets the Filamenting temperature-sensitive mutant Z (FtsZ) bacterial cell division protein and was granted Qualified Infectious Disease Product (QIDP) designation by the FDA. It may also be possible to develop a FtsZ drug candidate targeting Gram-negative bacteria in the future. Our Efflux Pump Inhibitors (EPIs) represent a new drug class against Gram-negative multidrug-resistant (MDR) pathogens. Bacterial efflux pumps act like bilge pumps by flushing antibiotics out of the bacterial cell and are responsible for antibiotic resistance in many gram-negative strains. TAXIS Pharmaceuticals EPIs have shown that they can resurrect the activity, potency and effectiveness of multiple classes of antibiotics including Macrolides, Cephalosporins, Monobactams, Antimycobacterials, Tetracyclines, Fluoroquinolones and Sulfanomides. Current data reveals synergy with 28 currently approved and marketed antibiotics that no longer work or now require high doses to have any effect.
CONTACT
Gregory G. Mario, CEO
gmario@taxispharma.com
www.taxispharma.com
TAXIS Pharmaceuticals, Inc.
9 Deerpark Drive
Monmouth Junction, NJ 08852
(732) 230-3074